natgillin/translations-raw huggingface dataset:
The most frequently reported (medicine-related treatment-emergent) adverse events in combination therapy (Caelyx + bortezomib) were nausea (40%), diarrhoea (35%), neutropaenia (33%), thrombocytopaenia (29%), vomiting (28%), fatigue (27%), and constipation (22%).
Najčešće zabilježene nuspojave (povezane s lijekom koje se javljaju za vrijeme liječenja) u kombiniranoj terapiji (Caelyx + bortezomib) bile su mučnina (40%), proljev (35%), neutropenija (33%), trombocitopenija (29%), povraćanje (28%), umor (27%) i zatvor (22%).
The most frequently reported adverse drug reactions (ADRs) (incidence ≥ 10% in the INTELENCE arm) of all intensities occurring in the Phase III studies were rash (19.2% in the INTELENCE arm versus 10.9% in the placebo arm), diarrhoea (18.0% in the INTELENCE arm versus 23.5% in the placebo arm), nausea (14.9% in the INTELENCE arm versus 12.7% in the placebo arm) and headache (10.9% in the INTELENCE arm versus 12.7% in the placebo arm).
Najčešće prijavljene nuspojave na lijek (ADR; eng. adverse drug reaction) (incidencija ≥ 10% u grupi s INTELENCEom) svih intenziteta koje su se pojavile u kliničkim ispitivanjima faze III bile su osip (19,2% u skupini koja je primala INTELENCE u odnosu na 10,9% u skupini na placebu), dijareja (18,0% u skupini koja je primala INTELENCE u odnosu na 23,5% u skupini na placebu), mučnina (14,9% u skupini koja je primala INTELENCE u odnosu na 12,7% u skupini na placebu) i glavobolja (10,9% u skupini koja je primala INTELENCE u odnosu na 12,7% u skupini na placebu).
The most frequently reported adverse drug reactions (ADRs) were upper respiratory tract infections (most frequently nasopharyngitis, rhinitis).
Najučestalije prijavljene nuspojave bile su infekcije gornjeg dijela dišnog sustava (najčešće nazofaringitis, rinitis).
The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia) and fatigue/asthenia.
Najčešće zabilježene nuspojave među bolesnicima koji su uzimali ritonavir sam ili u kombinaciji s drugim antiretrovirusnim lijekovima bili su poremećaji probavnog sustava (uključujući proljev, mučninu, povraćanje, bol u gornjem i donjem abdomenu, neurološki poremećaji (uključujući paresteziju i oralnu paresteziju) i umor/astenija.
The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhoea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paraesthesia and oral paraesthesia) and fatigue/asthenia.
Najčešće zabilježene nuspojave među bolesnicima koji su uzimali ritonavir sam ili u kombinaciji s drugim antiretrovirusnim lijekovima bili su poremećaji probavnog sustava (uključujući proljev, mučninu, povraćanje, bol u gornjem i donjem abdomenu, neurološki poremećaji (uključujući paresteziju i oralnu paresteziju) i umor/astenija.
The most frequently reported adverse drug reactions are decreased therapeutic response, pyrexia, rash, venous thromboembolic events, pruritus and urticaria.
Najčešće prijavljivane nuspojave su smanjen terapijski odgovor, pireksija, osip, venska tromboembolija, svrbež i urtikarija.
The most frequently reported adverse effects with leflunomide are: mild increase in blood pressure, leucopenia, paraesthesia, headache, dizziness, diarrhoea, nausea, vomiting, oral mucosal disorders (e.g. aphthous stomatitis, mouth ulceration), abdominal pain, increased hair loss, eczema, rash (including maculo-papular rash), pruritus, dry skin, tenosynovitis, CPK increased, anorexia, weight loss (usually insignificant), asthenia, mild allergic reactions and elevation of liver parameters (transaminases (especially ALT), less often gamma-GT, alkaline phosphatise, bilirubin))
Najčešće zabilježene nuspojave tijekom primjene leflunomida su: blagi porast krvnog tlaka, leukopenija, parestezija, glavobolja, omaglica, proljev, mučnina, povraćanje, poremećaji sluznice usne šupljine (npr. aftozni stomatitis, ulceracije u ustima), bol u trbuhu, pojačani gubitak kose, ekcem, osip (uključujući makulopapulozni osip), svrbež, suha koža, tenosinovitis, povećanje CPK, anoreksija, gubitak težine (obično beznačajan), astenija, blage alergijske reakcije i porast jetrenih parametara (transaminaze (osobito ALT), manje često gama-GT, alkalna fosfataza, bilirubin).
The most frequently reported adverse event from these trials judged probably or possibly related to imiquimod cream was application site reactions (22% of imiquimod treated patients).
Najčešće prijavljene nuspojave tijekom tih ispitivanja koje su ocijenjene kao vjerojatno ili moguće povezane s liječenjem imikvimod kremom bile su reakcije na mjestu primjene (22% bolesnika liječenih imikvimodom).
The most frequently reported adverse events from the trials judged probably or possibly related to imiquimod cream are application site disorders, with a frequency of 28.1%.
Najčešće prijavljene nuspojave u navedenim ispitivanjima, koje su ocijenjene kao vjerojatno ili moguće povezane s liječenjem imikvimod kremom bile su reakcije na mjestu primjene s učestalošću od 28,1%.
The most frequently reported adverse reaction during treatment is hypoglycaemia (see section ‘Description of selected adverse reactions’ below).
Najčešće prijavljena nuspojava tijekom liječenja je hipoglikemija (vidjeti dio ‘Opis odabranih nuspojava’ u nastavku).
The most frequently reported adverse reaction during treatment is hypoglycaemia (see section ‘Description of selected adverse reactions’ below).
Najčešće prijavljena nuspojava tijekom liječenja je hipoglikemija (vidjeti ‘Opis odabranih nuspojava’ u nastavku).
The most frequently reported adverse reaction during treatment is hypoglycaemia, please see section c below.
Najčešće zabilježena nuspojava tijekom liječenja je hipoglikemija, molimo vidjeti odjeljak c u nastavku.
The most frequently reported adverse reaction for Rasilamlo in clinical trials was peripheral oedema, which occurred at a frequency lower than or equal to that of the corresponding amlodipine doses, but higher than with aliskiren;
Najčešće prijavljivana nuspojava lijeka Rasilamlo u kliničkim ispitivanjima bio je periferni edem čija je učestalost pojave bila niža ili jednaka onoj s odgovarajućim dozama amlodipina, ali viša od one s aliskirenom.
The most frequently reported adverse reaction was hypoglycaemia observed under the triple combination, linagliptin plus metformin plus sulphonylurea 14.6% versus 7.6% in placebo.
Najčešće prijavljena nuspojava bila je hipoglikemija, primijećena u trojnoj kombinaciji, linagliptin plus metformin plus sulfonilureja, 14,6% u odnosu na 7,6% uz placebo.
The most frequently reported adverse reaction with umeclidinium/vilanterol was nasopharyngitis (9%).
Najčešće prijavljena nuspojava kod primjene umeklidinija/vilanterola bio je nazofaringitis (9%).
The most frequently reported adverse reactions (>10 %) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %).
Najčešće prijavljene nuspojave (> 10%) kod liječenja brivaracetamom bile su somnolencija (14,3%) i omaglica (11,0%).
The most frequently reported adverse reactions (occurring in ≥30% of patients) are hypertension (68.6%), diarrhoea (62.8%), decreased appetite (51.5%), weight decreased (49.1%), fatigue (45.8%), nausea (44.5%), proteinuria 36.9%), stomatitis (35.8%), vomiting (34.5%), dysphonia (34.1%), headache (34.1%), and palmar-plantar erythrodysaesthesia syndrome (PPE) (32.7%).
Najčešće zabilježene nuspojave (koje su nastale u ≥30% bolesnika) su hipertenzija (68,6%), proljev (62,8%), smanjeni apetit (51,5%), smanjena tjelesna težina (49,1%), umor (45,8%), mučnina (44,5%), proteinurija (36,9%), stomatitis (35,8%), povraćanje (34,5), disfonija (34,1%), glavobolja (34,1%) i sindrom palmarno- plantarne eritrodizestezije (PPE) (32,7%).
The most frequently reported adverse reactions (≥ 5%) among abatacept-treated patients were headache, nausea, and upper respiratory tract infections.
Najčešće prijavljene nuspojave (≥ 5%) u bolesnika liječenih abataceptom bile su glavobolja, mučnina i infekcije gornjeg dijela respiratornog trakta.
The most frequently reported adverse reactions (≥10% of patient with SLE treated with Benlysta plus standard of care and at a rate ≥1% greater than placebo) were nausea, diarrhoea, and pyrexia.
Najčešće prijavljene nuspojave (≥10% bolesnika sa SLE-om liječenih lijekom Benlysta u kombinaciji sa standardnom terapijom, te sa stopom ≥1% višom od placeba), bile su mučnina, proljev i pireksija.
The most frequently reported adverse reactions across the entire study period in the study eye of patients who received OZURDEX were cataract and elevated IOP (see below).
Najčešće prijavljene nuspojave na ispitivanom oku tijekom čitavog razdoblja ispitivanja u bolesnika koji su primili OZURDEX bile su katarakta i povišeni IOT (vidi u nastavku).
The most frequently reported adverse reactions after Vaxelis administration were irritability, crying, somnolence, injection site reactions (pain, erythema, swelling), pyrexia (≥38oC), decreased appetite, and vomiting.
Najčešće prijavljene nuspojave nakon primjene cjepiva Vaxelis bile su razdražljivost, plakanje, somnolencija, reakcije na mjestu injiciranja (bol, eritem, oticanje), pireksija (≥38 oC), smanjen apetit i povraćanje.
The most frequently reported adverse reactions are local skin responses including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration at the application site of ingenol mebutate gel, see table 1 for MedDRA terms.
Najčešće prijavljivane nuspojave su lokalne kožne reakcije uključujući eritem, ljuskanje/ljuštenje, krastanje, oticanje, vezikulaciju/stvaranje pustula i eroziju/ulceraciju na mjestu primjene ingenol mebutat gela; vidjeti tablicu 1 za MedDRA izraze.
The most frequently reported adverse reactions associated with Resolor 2mg therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain (13.7%), nausea (13.7%) and diarrhoea (12.0%)).
Najčešće prijavljene nuspojave povezane s terapijom lijekom Resolor 2 mg jesu glavobolja (17,8%) i gastrointestinalni simptomi (bol u trbuhu (13,7%), mučnina (13,7%) i proljev (12,0%)).
The most frequently reported adverse reactions associated with SevoFlo administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
Najčešće zabilježene nuspojave povezane s primjenom anestetika SevoFlo bile su hipotenzija, praćena tahipnejom, napetošću mišića, ekscitacijom, apnejom, mišićnim fascikulacijama i povraćanjem.
The most frequently reported adverse reactions associated with Sevohale administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
Najčešće zabilježene nuspojave povezane s primjenom anestetika Sevohale bile su hipotenzija, praćena tahipnejom, napetošću mišića, ekscitacijom, apnejom, mišićnim fascikulacijama i povraćanjem.
The most frequently reported adverse reactions considered possibly or probably related to Atripla among patients treated up to 48 weeks in study AI266073 were psychiatric disorders (16%), nervous system disorders (13%), and gastrointestinal disorders (7%).
Najčešće zabilježene nuspojave u pacijenata koji su liječeni do 48 tjedana u ispitivanju AI266073 za koje se smatra da su moguće ili vjerojatno povezane s Atriplom bile su psihijatrijski poremećaji (16%), poremećaji živčanog sustava (13%) i poremećaji probavnog sustava (7%).
The most frequently reported adverse reactions considered possibly or probably related to dolutegravir and abacavir/lamivudine [pooled data from 679 anti retroviral naïve subjects receiving this combination in the Phase IIb to IIIb clinical trials, see section 5.1], were nausea (12%), insomnia (7%), dizziness (6%) and headache (6%).
Najčešće prijavljene nuspojave čija se povezanost s primjenom dolutegravira i abakavira/lamivudina smatra mogućom ili vjerojatnom [objedinjeni podaci prikupljeni u 679 ispitanika koji prethodno nisu bili liječeni antiretroviroticima i koji su primali spomenutu kombinaciju u kliničkim ispitivanjima faze IIb do IIIb, vidjeti dio 5.1], bile su mučnina (12%), nesanica (7%) omaglica (6%) i glavobolja (6%).
The most frequently reported adverse reactions considered possibly or probably related to Stribild in clinical studies of treatment-naïve patients were nausea (16%) and diarrhoea (12%) (pooled data from Phase 3 clinical studies GS-US-236-0102 and GS-US-236-0103, through 144 weeks).
Najčešće zabilježene nuspojave u kliničkim ispitivanjima na pacijentima koji prethodno nisu bili liječeni, a za koje se smatra da su moguće ili vjerojatno povezane sa Stribildom, bile su mučnina (16%) i proljev (12%) (objedinjeni podaci iz faze 3 kliničkih ispitivanja GS US 236 0102 i GS US 236
The most frequently reported adverse reactions during treatment were headache and nausea, occurring at 5 % or greater.
Najčešće prijavljivane nuspojave tijekom liječenja bile su glavobolja i mučnina, čija je učestalost iznosila 5% ili više.
The most frequently reported adverse reactions during treatment were headache and nausea, occurring at 5% or greater.
Najčešće prijavljivane nuspojave tijekom liječenja bile su glavobolja i mučnina, čija je učestalost iznosila 5% ili više.
The most frequently reported adverse reactions during treatment with Xultophy were hypoglycaemia and gastrointestinal adverse reactions (see section ‘Description of selected adverse reactions’ below).
Najčešće prijavljene nuspojave tijekom liječenja lijekom Xultophy bile su hipoglikemija i gastrointestinalne nuspojave (vidjeti dio ‘Opis odabranih nuspojava’ u nastavku).
The most frequently reported adverse reactions from the clinical trials were headache (44%), hypoglycaemia (28%), vomiting (26%), injection site hypertrophy (17%), and otitis media (17%).
Najčešće prijavljene nuspojave iz kliničkih ispitivanja bile su su glavobolja (44%), hipoglikemija (28%), povraćanje (26%), hipertrofija na mjestu injiciranja (17%) i otitis media (17%) .
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking emtricitabine+tenofovir alafenamide in combination with elvitegravir+cobicistat were nausea (10%), diarrhoea (7%), and headache (6%).
Najčešće zabilježene nuspojave u kliničkim ispitivanjima u bolesnika koji prethodno nisu bili liječeni i primali su emtricitabin+tenofoviralafenamid u kombinaciji s elvitegravirom+kobicistatom bile su mučnina (10%), proljev (7%) i glavobolja (6%).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking rilpivirine hydrochloride in combination with emtricitabine+tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%).
Najčešće zabilježene nuspojave u kliničkim ispitivanjima u bolesnika koji prethodno nisu bili liječeni i primali su rilpivirinklorid u kombinaciji s emtricitabinom+tenofovirdizoproksilfumaratom bile su mučnina (9%), omaglica (8%), abnormalni snovi (8%), glavobolja (6%), proljev (5%) i nesanica (5%).
The most frequently reported adverse reactions in clinical studies through 96 weeks were nausea (10%), diarrhoea (7%), and headache (6%) (pooled data from Phase 3 clinical studies GS-US-292-0104 and GS-US-292-0111 in 866 treatment-naïve adult patients receiving Genvoya).
Najčešće zabilježene nuspojave u kliničkim ispitivanjima tijekom 96 tjedana bile su mučnina (10%), proljev (7%) i glavobolja (6%) (objedinjeni podaci iz kliničkih ispitivanja faze 3 GS-US-292-0104 i GS-US-292-0111 provedenih u 866 odraslih bolesnika koji prethodno nisu bili liječeni i primali su lijek Genvoya).
The most frequently reported adverse reactions in patients who received OZURDEX were increased intraocular pressure (24.0 %) and conjunctival haemorrhage (14.7 %).
Najčešće prijavljene nuspojave kod bolesnika koji su primili OZURDEX bile su povišeni očni tlak (24,0%) i krvarenje iz konjunktive (14,7%).
The most frequently reported adverse reactions in SPRYCEL-treated patients with resistance or intolerance to prior imatinib therapy were fluid retention (including pleural effusion), diarrhoea, headache, nausea, skin rash, dyspnoea, haemorrhage, fatigue, musculoskeletal pain, infection, vomiting, cough, abdominal pain and pyrexia.
Najčešće zabilježene nuspojave u bolesnika liječenih lijekom SPRYCEL koji ne podnose ili su otporni na prethodnu terapiju imatinibom bile su zadržavanje tekućine (uključujući pleuralni izljev), proljev, glavobolja, mučnina, kožni osip, dispneja, hemoragija, umor, mišićno-koštana bol, infekcija, povraćanje, kašalj, bol u abdomenu i pireksija.
The most frequently reported adverse reactions in the ospemifene 60 mg group were hot flushes (7.5%)
Najčešće prijavljene nuspojave u skupini koja je primala 60 mg ospemifena bile su navale vrućine (7,5%).
The most frequently reported adverse reactions leading to discontinuation were infection and diarrhoea for ONIVYDE+5-FU/LV arm, and vomiting and diarrhoea for the monotherapy arm.
Najčešće prijavljivane nuspojave koje su vodile prekidu liječenja bile su infekcija i proljev u skupini ONIVYDE+5-FU/LV te povraćanje i proljev u skupini s monoterapijom.
The most frequently reported adverse reactions occurring in patients receiving tedizolid phosphate in the pooled controlled Phase 3 clinical studies (tedizolid 200 mg once daily for 6 days) were nausea (6.9%), headache (3.5%), diarrhoea (3.2%) and vomiting (2.3%), and were generally mild to moderate in severity.
Najčešće prijavljivane nuspojave koje su se pojavile u bolesnika liječenih tedizolidfosfatom iz objedinjenih kliničkih ispitivanja faze 3 (tedizolid 200 mg jedanput na dan tijekom 6 dana) bile su mučnina (6,9%), glavobolja (3,5%), proljev (3,2%) i povraćanje (2,3%), a bile su općenito blage do umjerene težine.
The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fatigue and headache.
Najčešće prijavljene nuspojave zabilježene tijekom ispitivanja faze2b/3, bile su mučnina, proljev, umor i glavobolja.
The most frequently reported adverse reactions related to Viramune prolonged-release therapy in treatment naïve patients (including lead-in phase with immediate-release) in clinical study 1100.1486 (VERxVE) were rash, nausea, liver function test abnormal, headache, fatigue, hepatitis, abdominal pain, diarrhoea and pyrexia.
Najčešće prijavljene nuspojave povezane s terapijom Viramune tableta s produljenim oslobađanjem u liječenju prethodno neliječenih bolesnika (uključujući uvodno razdoblje i liječenje formulacijom s trenutnim oslobađanjem) u kliničkom ispitivanju 1100.1486 (VERxVE) bile su osip, mučnina, abnormalnosti u testovima jetrene funkcije, glavobolja, umor, hepatitis, bol u abdomenu, proljev i pireksija.
The most frequently reported adverse reactions related to Viramune prolonged-release therapy in treatment naïve patients (including lead-in phase with immediate-release) in clinical study 1100.1486 (VERxVE) were rash, nausea, liver function test abnormal, headache, fatigue, hepatitis, abdominal pain, diarrhoea and pyrexia.
Najčešće prijavljene nuspojave povezane s terapijom Viramuneom tableta s produljenim oslobađanjem u liječenju prethodno neliječenih bolesnika (uključujući uvodno razdoblje i liječenje formulacijom s trenutnim oslobađanjem) u kliničkom ispitivanju 1100.1486 (VERxVE) bile su osip, mučnina, abnormalnosti u testovima jetrene funkcije, glavobolja, umor, hepatitis, bol u abdomenu, proljev i vrućica.
The most frequently reported adverse reactions to elvitegravir were diarrhoea (7.1%) and nausea (4.0%) (see Table 3).
Najčešće prijavljene nuspojave na elvitegravir bile su proljev (7,1%) i mučnina (4,0%) (vidjeti tablicu 3).
The most frequently reported adverse reactions were bone pain (very common [ ≥ 1/10]) and musculoskeletal pain (common).
Najčešće prijavljene nuspojave bile su bol u kostima (vrlo često [≥ 1/10]) i mišićno-koštana bol (često).
The most frequently reported adverse reactions were bone pain (very common [≥ 1/10]) and musculoskeletal pain (common).
Najčešće prijavljene nuspojave bile su bol u kostima (vrlo često [≥ 1/10]) i mišićno-koštana bol (često).
The most frequently reported adverse reactions were fatigue, anaemia (see section 4.4), nausea, headache, and dysgeusia.
Najčešće prijavljene nuspojave bile su umor, anemija (vidjeti dio 4.4), mučnina, glavobolja i disgeuzija.
The most frequently reported adverse reactions were fatigue, headache, pruritus, anaemia, influenza- like illness, nausea, insomnia, neutropenia, asthenia, rash, decreased appetite, dry skin, alopecia, pyrexia, myalgia, irritability, cough, diarrhoea, dyspnoea and arthralgia.
Najčešće prijavljene nuspojave bile su umor, glavobolja, pruritus, anemija, bolest nalik gripi, mučnina, nesanica, neutropenija, astenija, osip, smanjen tek, suha koža, alopecija, pireksija, mialgija, razdražljivost, kašalj, proljev, dispneja i artralgija.
The most frequently reported adverse reactions were gastrointestinal symptoms (abdominal pain [8%], flatulence [4%], constipation [4%], abdominal discomfort [2%]/distension [2%] and diarrhoea [3%]) and these were mainly mild to moderate in severity.
Najčešće zabilježene nuspojave su gastrointestinalni simptomi (bol u abdomenu [8 %], nadutost [4 %], zatvor [4 %], nelagoda [2 %]/distenzija [2 %] u abdomenu i proljev [3 %]) uglavnom blage do umjerene jačine.
The most frequently reported adverse reactions were injection site reactions, and hepatic enzymes increased.
Najčešće prijavljene nuspojave bile su reakcije na mjestu injiciranja i povišene vrijednosti jetrenih enzima.
The most frequently reported adverse reactions were IRRs (48%); see section 4.4. Other frequently reported adverse reactions (≥ 20%) were fatigue (39%), pyrexia (21%), cough (21%), nausea (27%),
Najčešće prijavljene nuspojave bile su reakcije na infuziju (48%); vidjeti dio 4.4. Ostale često prijavljene nuspojave (≥ 20%) bile su umor (39%), pireksija (21%), kašalj (21%), mučnina (27%), bol
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache ,fatigue and dizziness.
Najčešće prijavljene nuspojave su nazofaringitis, izrazita pospanost, glavobolja, umor i omaglica.
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.
Najčešće prijavljene nuspojave su nazofaringitis, izrazita pospanost, glavobolja, umor i omaglica.
The most frequently reported adverse reactions with Bretaris Genuair were headache (6.6%) and nasopharyngitis (5.5%).
Najčešće prijavljene nuspojave lijeka Bretaris Genuair bile su glavobolja (6,6%) i nazofaringitis (5,5%).
The most frequently reported adverse reactions with Brimica Genuair were nasopharyngitis (7.9%) and headache (6.8%).
Najčešće prijavljene nuspojave lijeka Brimica Genuair bile su nazofaringitis (7,9%) i glavobolja (6,8%).
The most frequently reported adverse reactions with dexmedetomidine are hypotension, hypertension and bradycardia, occurring in approximately 25%, 15% and 13% of patients respectively.
Najčešće zabilježene nuspojave deksmedetomidina su hipotenzija, hipertenzija i bradikardija, koje se pojavljuju u približno 25%, 15% odnosno 13% bolesnika.
The most frequently reported adverse reactions with Duaklir Genuair were nasopharyngitis (7.9%) and headache (6.8%).
Najčešće prijavljene nuspojave lijeka Duaklir Genuair bile su nazofaringitis (7,9%) i glavobolja (6,8%).
The most frequently reported adverse reactions with Eklira Genuair were headache (6.6%) and nasopharyngitis (5.5%).
Najčešće prijavljene nuspojave lijeka Eklira Genuair bile su glavobolja (6,6%) i nazofaringitis (5,5%).
The most frequently reported adverse reactions with Incruse were nasopharyngitis and upper respiratory tract infection.
Najčešće prijavljivane nuspojave kod primjene lijeka Incruse bile su nazofaringitis i infekcija gornjeg dišnog sustava.
The most frequently reported adverse reactions with lacosamide treatment were dizziness, headache, nausea and diplopia.
Najčešće prijavljivane nuspojave tijekom liječenja lakozamidom bile su omaglica, glavobolja, mučnina i diplopija.